CT-868

N/A

Report date: 2026/02/06 20:01:23
NME

Base Information

Drug NameCT-868
Drug Alias Namedual GLP-1R/GIPR Modulator (Carmot Therapeutics)GLP-1/GIP receptor agonist (Carmot Therapeutics)dual GLP-1 and GIP receptor modulator (Carmot Therapeutics)dual glucagon-like peptide 1 receptor/gastric inhibitory polypeptide receptor agonists (Carmot Therapeutics)CT-868 +[6] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonistsGlucose-Dependent Insulinotropic Polypeptide Receptor agonists
TargetsGlucagon-like peptide 1 receptorGlucose-Dependent Insulinotropic Polypeptide Receptor
Therapy Area/IndicationsOverweightObesityDiabetes Mellitus, Type 2 +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMexico
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCarmot Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCarmot Therapeutics IncF. Hoffmann-La Roche Ltd
Inactive CompaniesN/A
Active IndicationsOverweightObesityDiabetes Mellitus, Type 2 +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A